Genetic Technologies LtdNASDAQ:GENENASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7650
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.7650/ 5
- Ask / Lots0.7650/ 6
- Open / Previous Close--- / 0.7650
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Oct 11, 2024
BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV, from 9:01AM ET on Friday Oct 11, 2024 by Dow Jones
9:01AM ET on Friday Oct 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Genetic Technologies Ltd | 6.3M | -0.4x | --- |
Syra Health Corp | 4.0M | -0.6x | --- |
CompuMed Inc | 3.7M | -21.2x | --- |
Kindly MD Inc | 5.1M | -1.8x | --- |
Avalon Globocare Corp | 3.7M | -0.2x | --- |
Ethema Health Corp | 4.6M | 2.7x | --- |
Company Information
Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor
Contact Information
- Headquarters
- 60-66 Hanover St, FitzroyMELBOURNE, VIC, Australia 3065
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Peter Rubinstein
- Chief Executive Officer
- Simon Morriss
- Chief Financial Officer, Company Secretary
- Mark Ziirsen
- Chief Executive Officer - EasyDNA
- Kevin Camilleri
- Chief Scientific Officer
- Richard Allman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.3M |
|---|---|
Revenue (TTM) | $5.1M |
Shares Outstanding | 8.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.12 |
EPS | $-1.83 |
Book Value | $0.28 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 1.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -157.67% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
